James E. Flynn 13D and 13G filings for Larimar Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-15 4:37 pm Purchase | 2024-03-14 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 21,273,474 33.320% | 8,300 (+0.04%) | Filing |
| 2024-02-16 2:11 pm Purchase | 2024-02-16 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 21,265,174 34.820% | 4,291,539 (+25.28%) | Filing |
| 2024-02-15 5:20 pm Unchanged | 2024-02-13 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 16,973,635 39.200% | 0 (Unchanged) | Filing |
| 2023-03-16 5:41 pm Purchase | 2023-03-14 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 16,973,635 39.200% | 10,606 (+0.06%) | Filing |
| 2022-09-16 5:19 pm Purchase | 2022-09-16 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 16,963,029 42.450% | 11,126,786 (+190.65%) | Filing |
| 2021-07-02 5:08 pm Purchase | 2021-06-30 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,836,243 32.940% | 686,171 (+13.32%) | Filing |
| 2021-05-26 1:48 pm Unchanged | 2021-05-25 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,150,072 33.500% | 0 (Unchanged) | Filing |
| 2021-05-21 5:05 pm Purchase | 2021-05-21 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,150,072 33.500% | 5,533 (+0.11%) | Filing |
| 2020-07-01 4:01 pm Sale | 2020-06-26 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,144,539 33.500% | -946,711 (-15.54%) | Filing |
| 2020-06-08 5:10 pm Purchase | 2020-05-28 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 6,091,250 39.760% | 6,091,250 (New Position) | Filing |